Valuation: COMPASS Pathways plc

Market Cap 1.46B 1.28B 1.2B 1.1B 2.06B 140B 2.1B 14.2B 5.56B 69.37B 5.5B 5.38B 240B P/E 2026 *
-11.6x
P/E 2027 * -7.47x
Enterprise Value 1.04B 913M 850M 782M 1.47B 99.37B 1.49B 10.08B 3.95B 49.28B 3.9B 3.82B 170B EV / Sales 2026 *
-
EV / Sales 2027 * 16.2x
Free-Float
25.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: COMPASS Pathways plc

1 day-3.73%
1 week-10.92%
Current month-23.32%
1 month-26.79%
3 months+28.55%
6 months+61.70%
Current year+57.25%
1 week 10.59
Extreme 10.59
11.95
1 month 10.59
Extreme 10.59
15.39
Current year 4.88
Extreme 4.88
15.4
1 year 3.92
Extreme 3.92
15.4
3 years 2.25
Extreme 2.25
15.4
5 years 2.25
Extreme 2.25
49.52
10 years 2.25
Extreme 2.25
61.69
Manager TitleAgeSince
Chief Executive Officer 61 31/07/2022
Director of Finance/CFO 54 29/02/2024
Chief Tech/Sci/R&D Officer 66 30/04/2024
Director TitleAgeSince
Chairman 74 28/03/2024
Director/Board Member 69 31/03/2020
Director/Board Member 67 28/02/2021
Date Insider Type Main position Quantity % Market Cap.
27/05/26 Free

Director

21,110 0.0220%
27/05/26 Free

Director

21,110 0.0220%
27/05/26 Free

Chairman

30,158 0.0314%
Change 5-day change 1-year change 3-year change Capi.($)
-3.73%-10.92%+150.00%+19.36% 1.46B
+0.29%+4.85%-3.07%+11.32% 47.88B
-2.24%+0.31%+393.45%+615.13% 39.09B
+1.40%+3.69%+12.21%+46.79% 36.75B
+13.94%+20.49%+22.85%+7.42% 40.55B
-0.73%+3.38%+4.94%+41.45% 27.96B
+0.40%-0.30% - - 16.77B
-3.12%+7.39%+26.03%+124.08% 15.94B
-1.69%-4.39%+1.47%+7.83% 13.55B
+6.79%+8.17%-4.97%-28.52% 13.81B
Average +1.15%+3.08%+66.99%+93.87% 25.38B
Weighted average by Cap. +2.17%+4.94%+73.13%+124.41%

Financials

2026 *2027 *
Net sales - 59.43M 52.15M 48.57M 44.67M 83.74M 5.68B 85.17M 576M 226M 2.82B 223M 218M 9.73B
Net income -98.16M -86.14M -80.22M -73.78M -138M -9.38B -141M -952M -372M -4.65B -368M -361M -16.07B -198M -174M -162M -149M -279M -18.89B -283M -1.92B -750M -9.37B -742M -726M -32.37B
Net Debt -424M -372M -347M -319M -598M -40.52B -608M -4.11B -1.61B -20.09B -1.59B -1.56B -69.43B -504M -443M -412M -379M -711M -48.18B -723M -4.89B -1.91B -23.89B -1.89B -1.85B -82.55B
Logo COMPASS Pathways plc
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Employees
156
Date Price Change Volume
28/07/26 US$10.85 -3.73% 2,670,643
27/07/26 US$11.27 +0.09% 2,983,857
24/07/26 US$11.26 -3.84% 3,627,158
23/07/26 US$11.71 -1.84% 1,822,118
22/07/26 US$11.93 -2.05% 1,726,461
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
10.85USD
Average target price
23.75USD
Spread / Average Target
+118.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPS Stock